Article Text

Download PDFPDF
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy
  1. M C Genovese1,
  2. M Schiff2,
  3. M Luggen3,
  4. J-C Becker4,
  5. R Aranda4,
  6. J Teng4,
  7. T Li4,
  8. N Schmidely5,
  9. M Le Bars5,
  10. M Dougados1,6
  1. 1
    Stanford University, Division of Immunology and Rheumatology, 1000 Welch Road #203, Palo Alto, CA, 94304, USA
  2. 2
    Denver Arthritis Clinic, Denver, CO, USA
  3. 3
    University of Cincinnati Medical Center, Cincinnati, OH, USA
  4. 4
    Bristol-Myers Squibb, Princeton, NJ, USA
  5. 5
    Bristol-Myers Squibb, Rueil-Malmaison, France
  6. 6
    Hopital Cochin, Descartes University, Paris, France
  1. Dr Mark Genovese, Stanford University, Division of Immunology and Rheumatology, 1000 Welch Road #203, Palo Alto, CA, 94304, USA; genovese{at}


Objective: To evaluate the safety and efficacy of abatacept during 2 years of the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trial in patients with rheumatoid arthritis.

Methods: Patients completing the 6-month, double-blind period were eligible to enter the long-term extension; patients received abatacept ∼10 mg/kg, plus disease-modifying antirheumatic drugs. Safety and efficacy (American College of Rheumatology (ACR) criteria responses, DAS28 (C-reactive protein), HAQ-DI, SF-36, Medical Outcomes Study Sleep Problems Index, fatigue VAS) were assessed through 2 years.

Results: 317 patients (218 from the abatacept and 99 from the placebo group) entered and 222 (70%) completed 18 months of long-term extension treatment. The incidence and type of adverse events were consistent between the double-blind and cumulative (double-blind plus long-term extension) periods. Rates of serious adverse events were 25.6 and 23.4 per 100 patient-years in the double-blind versus cumulative period. At 6 months and 2 years, using non-responder analyses, ACR responses in abatacept-treated patients were: ACR 20, 59.4% and 56.2%; ACR 50, 23.5% and 33.2%; ACR 70, 11.5% and 16.1%; HAQ-DI responses were 54.4% and 47.9%. At 6 months and 2 years, using post-hoc as-observed analyses, the percentage of patients (95% confidence interval) achieving DAS28 (C-reactive protein) low disease activity score (⩽3.2) and DAS28 (C-reactive protein)-defined remission (<2.6) increased from 18.3% (13.0, 23.5) to 32.0% (24.6, 39.4) and 11.1% (6.8, 15.3) to 20.3% (13.9, 26.6). Clinically meaningful improvements in SF-36, pain, fatigue and sleep problems were also maintained throughout the 2 years of abatacept treatment.

Conclusion: No unique safety observations were reported during open-label exposure. Improvements in the signs and symptoms of rheumatoid arthritis, physical function and health-related quality of life observed after 6 months, were maintained throughout the 2 years in this population with difficult-to-treat disease.

Trial registration number: NCT00124982.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.

  • The Food and Drug Administration registration number for this clinical trial is NCT00124982.